Current Report Filing (8-k)
March 16 2020 - 4:57PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
March 16, 2020
Mustang Bio, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
|
001-38191
(Commission File Number)
|
|
47-3828760
(IRS Employer Identification No.)
|
377 Plantation Street
Worcester, Massachusetts 01605
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act.
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act.
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
MBIO
|
NASDAQ Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 2.02 Results of Operations and Financial Condition.
On March 16, 2020,
Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year
ended December 31, 2019. A copy of such press release is being furnished as Exhibit 99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
MUSTANG BIO, INC.
|
|
(Registrant)
|
|
|
Date: March 16, 2020
|
|
|
By:
|
|
/s/ Manuel Litchman, M.D.
|
|
Name:
|
|
Manuel Litchman, M.D.
|
|
Title:
|
|
President and Chief Executive Officer
|
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From May 2023 to May 2024